[go: up one dir, main page]

AR050644A1 - Derivados de anilina sustituidos - Google Patents

Derivados de anilina sustituidos

Info

Publication number
AR050644A1
AR050644A1 ARP050103796A ARP050103796A AR050644A1 AR 050644 A1 AR050644 A1 AR 050644A1 AR P050103796 A ARP050103796 A AR P050103796A AR P050103796 A ARP050103796 A AR P050103796A AR 050644 A1 AR050644 A1 AR 050644A1
Authority
AR
Argentina
Prior art keywords
alky
cycloalk
ilo
alkyl
cycloalkyl
Prior art date
Application number
ARP050103796A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36654136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050644(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR050644A1 publication Critical patent/AR050644A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/29—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente se refiere a derivados de anilina de la formula general (1) o a las sales de los mismos y su uso, por ejemplo para aumentar el flujo de iones en un canal de potasio en un mamífero. Reivindicacion 1: Un compuesto que tiene la formula general (1) o sales del mismo en donde Z es O o S; y q es 0 o 1; y cada uno de R1 y R2 es seleccionado independientemente del grupo que consiste en halogeno, ciano, amino, C1-6-alqu(en/in)ilo, C3-8-cicloalqu(en)ilo, C3-8-cicloalqu(en)il-C1-6- alqu(en/in)ilo, C3-8-heterocicloalqu(en)ilo, arilo, heteroarilo, halo-C1-6-alqu(en/in)ilo, halo-C3-8-cicloalqu(en)ilo, halo-C3-8-cicloalqu(en)il-C1-6-alqu(en/in)ilo, C1-6-alqu(en/in)iloxi, C3-8-cicloalqu(en)iloxi, C3-8-cicloalqu(en)il-C1-6- alqu(en/in)iloxi, C3-8-heterocicloalqu(en)iloxi, y R3 es seleccionado del grupo que consiste en C1-8-alqu(en/in)ilo, C3-8-cicloalqu(en)ilo, C3-8-cicloalqu(en)il-C1-6-alqu(en/in)ilo, aril-C1-6-alqu(en/in)ilo, aril-C3-8-cicloalqu(en)ilo, aril-C3-8- cicloalqu(en)il-C1-6-alqu(en/in)ilo, C3-8-heterocicloalqu(en)il-C1-6-alqu(en/in)ilo, C1-6-alqu(en/in)il-C3-8-heterocicloalqu(en)il-C1-6-alqu(en/in)ilo, heteroaril-C1-6-alqu(en/in)ilo, heteroaril-C3-8-cicloalqu(en)ilo, heteroaril-C3-8-cicloalqu(en)il- C1-6-alqu(en/in)ilo, amino-C1-6-alqu(en/in)ilo, amino-C3-8-cicloalqu(en)ilo, amino-C3-8-cicloalqu(en)il-C1-6-alqu(en/in)ilo, C1-6-alqu(en/in)iloxi-C1-6-alqu(en/in)ilo, C3-8-cicloalqu(en)iloxi-C1-6-alqu(en/in)ilo, C3-8-cicloalqu(en)il-C1-6- alqu(en/in)iloxi-C1-6-alqu(en/in)ilo, halo-C1-6-alqu(en/in)ilo, halo-C3-8-cicloalqu(en)ilo, halo-C3-8-cicloalqu(en)il-C1-6-alqu(en/in)ilo, y R4 es seleccionado del grupo que consiste en halogeno, ciano, C1-6-alqu(en/in)ilo, C3-8-cicloalqu(en)ilo, C3- 8-cicloalqu(en)il-C1-6-alqu(en/in)ilo, C3-8-heterocicloalqu(en)ilo, arilo, heteroarilo, aril-C3-8-cicloalqu(en)ilo, aril-C3-8-cicloalqu(en)il-C1-6-alqu(en/in)ilo, aril-C3-8-heterocicloalqu(en)ilo, halo-C1-6-alqu(en/in)ilo, halo-C3-8- cicloalqu(en)ilo, halo-C3-8-cicloalqu(en)il-C1-6-alqu(en/in)ilo, halo-C1-6-alqu(en/in)ilo-C3-8-heterocicloalqu(en)il-C1-6-alqu(en/in)ilo, NR5R6 y R7NH-C1-6-alqu(en/in)ilo; en donde R5 y R6 son seleccionados independientemente del grupo que consiste en H, aril-C1-6-alqu(en/in)ilo, aril-C3-8-cicloalqu(en)ilo, aril-C3-8-cicloalqu(en)il-C1-6-alqu(en/in)ilo, C1-6-alqu(en/in)ilo, C3-8-cicloalqu(en)ilo, C3-8-cicloalqu(en)il-C1-6-alqu(en/in)ilo, heteroaril-C1-6-alqu(en/in)ilo, heteroaril-C3-8- cicloalqu(en)ilo y heteroaril-C3-8-cicloalqu(en)il-C1-6-alqu(en/in)ilo, con la condicion de que R5 y R6 no sean H al mismo tiempo; y R7 es seleccionado del grupo que consiste en C1-6-alqu(en/in)ilo, C3-8-cicloalqu(en)ilo, C3-8-cicloalqu(en)il-C1-6- alqu(en/in)ilo, arilo, halo-C1-6-alqu(en/in)ilo, halo-C3-8-cicloalqu(en)ilo, halo-C3-8-cicloalqu(en)il-C1-6-alqu(en/in)ilo, aril-C1-6-alqu(en/in)ilo, aril-C3-8-cicloalqu(en)ilo y heteroailo.
ARP050103796A 2004-09-13 2005-09-12 Derivados de anilina sustituidos AR050644A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200401394 2004-09-13

Publications (1)

Publication Number Publication Date
AR050644A1 true AR050644A1 (es) 2006-11-08

Family

ID=36654136

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103796A AR050644A1 (es) 2004-09-13 2005-09-12 Derivados de anilina sustituidos

Country Status (16)

Country Link
US (2) US7601870B2 (es)
EP (1) EP1791809A1 (es)
JP (1) JP2008512402A (es)
KR (1) KR20070058502A (es)
CN (1) CN101056845A (es)
AR (1) AR050644A1 (es)
AU (1) AU2005284501A1 (es)
BR (1) BRPI0515174A (es)
CA (1) CA2580131A1 (es)
EA (1) EA200700633A1 (es)
IL (1) IL181679A0 (es)
MX (1) MX2007002911A (es)
NO (1) NO20071843L (es)
UA (1) UA89503C2 (es)
WO (1) WO2006029623A1 (es)
ZA (1) ZA200702125B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
EP1983974A1 (en) 2006-02-07 2008-10-29 H. Lundbeck A/S Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
KR20090079191A (ko) 2006-08-23 2009-07-21 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서 ４-(ｎ-아자사이클로알킬) 아닐리드의 유도체
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ES2375417T3 (es) 2006-11-28 2012-02-29 Valeant Pharmaceuticals International Análogos 1,4-diamino bicíclicos de retigabina como moduladores de los canales de potasio.
EP2152677A1 (en) 2007-05-03 2010-02-17 NeuroSearch A/S Acetamide derivatives as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EA201070189A1 (ru) * 2007-08-01 2010-08-30 Х. Лундбекк А/С Применение соединений, открывающих калиевые каналы kcnq, для подавления симптомов или лечения расстройств или состояний, при которых нарушается дофаминергическая система
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
JP2011506390A (ja) * 2007-12-11 2011-03-03 ノイロサーチ アクティーゼルスカブ カリウムチャネル活性化因子として有用な、新規の２−ピロリジニル−３−アミド−６−アミノ−ピリジン誘導体
MX2010014461A (es) * 2008-06-24 2011-04-28 Valeant Pharmaceuticals Int Derivados de benciloxi anilida utiles como moduladores de canales de potasio.
CA2760825C (en) * 2009-06-03 2017-07-11 Marquette University Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
CN103073455B (zh) * 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
CN103508943B (zh) * 2012-06-29 2017-06-09 江苏先声药业有限公司 作为钾通道调节剂的化合物
AP3778A (en) * 2012-07-10 2016-08-31 Bayer Pharma AG Method for preparing substituted triazolopyridines
CN108250128A (zh) * 2012-09-27 2018-07-06 江苏先声药业有限公司 作为钾通道调节剂的化合物
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
CN104020195B (zh) * 2014-05-27 2016-03-09 安徽师范大学 双识别多巴胺印迹电化学传感器及其制备方法和应用
ES2871673T3 (es) * 2014-10-24 2021-10-29 Ono Pharmaceutical Co Activador de los canales KCNQ2-5
JP6197971B1 (ja) * 2016-04-22 2017-09-20 小野薬品工業株式会社 Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
MX2018012898A (es) * 2016-04-22 2019-01-30 Ono Pharmaceutical Co Polimorfismo cristalino del activador del canal controlado por voltaje de potasio de subfamilia kqt subtipos 2-5 (kcnq2-5).
RU2018147263A (ru) * 2016-06-10 2020-07-10 Сайфлуор Лайф Сайенсиз, Инк Фторированные 2-амино-4-(замещенные амино)фенилкарбаматные производные
EP3366683A1 (en) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
EP3724163A4 (en) * 2017-12-13 2021-07-28 SciFluor Life Sciences, Inc. FLUORINE DERIVATIVES 4- (AMINO SUBSTITUTE) PHENYL CARBAMATE
CN110511220B (zh) * 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CN108707087B (zh) * 2018-06-29 2020-10-16 河北医科大学 一种4-(对三氟甲基苄基)-3-氟-1,2,4三苯胺衍生物及其药物组合物与用途
CN112010808B (zh) * 2019-05-31 2021-11-30 上海挚盟医药科技有限公司 作为钾通道调节剂的四氢-1h-苯氮杂卓类化合物及其制备和应用
AU2020380961A1 (en) 2019-11-08 2022-05-26 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
MX2023009314A (es) 2021-02-09 2023-08-16 Xenon Pharmaceuticals Inc Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia.
WO2022211520A1 (ko) * 2021-04-02 2022-10-06 파렌키마바이오텍 주식회사 신규 화합물 및 이의 자가면역질환 치료 용도
CN116535353A (zh) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 作为钾通道调节剂的酰胺类化合物及其制备和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362992A (en) * 1965-05-27 1968-01-09 Schwartz Herbert Novel cycloalkenecarboxanilides
JPS5214745A (en) * 1975-07-23 1977-02-03 Yoshitomi Pharmaceut Ind Ltd Preparation of phenylcarbamic acid esters
NZ223847A (en) * 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
JPH106578A (ja) * 1996-06-21 1998-01-13 Canon Inc 印刷装置および印刷制御方法
DE69914931T2 (de) * 1998-10-09 2004-12-16 Janssen Pharmaceutica N.V. 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung
WO2001010380A2 (en) * 1999-08-04 2001-02-15 Icagen, Inc. Benzanilides as potassium channel openers
JP4223003B2 (ja) * 2002-05-29 2009-02-12 エフ．ホフマン−ラ ロシュ アーゲー 選択的モノアミンオキシダーゼｂインヒビターとしてのｎ−アシルアミノベンゼン誘導体
CA2519061A1 (en) * 2003-03-14 2004-09-23 H. Lundbeck A/S Substituted aniline derivatives
JP4551667B2 (ja) * 2003-09-26 2010-09-29 富士フイルム株式会社 液晶組成物及び液晶素子
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну

Also Published As

Publication number Publication date
WO2006029623A1 (en) 2006-03-23
US7601870B2 (en) 2009-10-13
MX2007002911A (es) 2007-04-27
EA200700633A1 (ru) 2007-10-26
US20100063044A1 (en) 2010-03-11
KR20070058502A (ko) 2007-06-08
EP1791809A1 (en) 2007-06-06
BRPI0515174A (pt) 2008-07-08
CN101056845A (zh) 2007-10-17
IL181679A0 (en) 2007-07-04
NO20071843L (no) 2007-04-11
CA2580131A1 (en) 2006-03-23
AU2005284501A1 (en) 2006-03-23
UA89503C2 (uk) 2010-02-10
ZA200702125B (en) 2008-09-25
US20060155121A1 (en) 2006-07-13
JP2008512402A (ja) 2008-04-24

Similar Documents

Publication Publication Date Title
AR050644A1 (es) Derivados de anilina sustituidos
CO5721002A2 (es) Derivados de acido 3-(4-benciloxifenil) propanoico
AR049951A1 (es) Derivados de ftalazina como inhibidores de parp
AR058776A1 (es) Compuesto de piridina condensado
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
CO5580803A2 (es) Derivados de piperidin-bencensulfonamida
NI201000018A (es) Derivado de oxopirazina y herbicida
RU2009141982A (ru) Пиримидиновые производные
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
AR047917A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos
CR9660A (es) Nuevo derivado de heterocicliden acetamida
AR053748A1 (es) Entidades quimicas, composiciones y metodos.
AR055619A1 (es) Diaminopirimidinas como moduladores p2x2/3
CO6241101A2 (es) Derivados de quinolina como inhibidores de la p13 quinasa
CO6160235A2 (es) Isoxazolinas insecticidas
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR074435A1 (es) Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.
PE20070009A1 (es) Tigeciclina y metodos para su preparacion
ES2523302T3 (es) Colorantes azoicos
AR070655A1 (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
AR029400A1 (es) Derivados de isoxazolcarboxamida, un metodo para su preparacion y una composicion farmaceutica que los comprende
AR063636A1 (es) Derivados de indol y de benzofurano-2-carboxamida
AR039111A1 (es) Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas
AR055420A1 (es) Derivados de pirimidina sustituidos
ATE431333T1 (de) Amino-propanolderivate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal